{
    "id": "35d22197-2c4e-2618-e063-6294a90adc3a",
    "indications": "celecoxib capsule indicated",
    "contraindications": "• lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) • oa : 200 mg daily 100 mg twice daily . ( 2.2 , 14.1 ) • rheumatoid arthritis : 100 200 mg twice daily . ( 2.3 , 14.2 ) • jra : 50 mg twice daily patients 10 kg 25 kg . 100 mg twice daily patients 25 kg . ( 2.4 , 14.3 ) • : 200 mg daily single dose 100 mg twice daily . effect observed 6 weeks , trial 400 mg ( single divided doses ) may benefit . ( 2.5 , 14.4 ) • ap pd : 400 mg initially , followed 200 mg dose needed first day . subsequent days , 200 mg twice daily needed . ( 2.6 , 14.5 ) hepatic impairment : reduce daily dose 50 % patients moderate hepatic impairment ( child-pugh class b ) . ( 2.7 , 8.6 , 12.3 ) poor metabolizers cyp2c9 substrates : consider dose reduction 50 % ( alternative management jra ) patients known suspected cyp2c9 poor metabolizers . ( 2.7 , 8.8 , 12.3 ) .",
    "warningsAndPrecautions": "celecoxib capsules 100 mg white white opaque hard gelatin capsules , imprinted `` cel `` cap & `` 100 mg `` body black ink supplied : ndc : 70518-3424-00 ndc : 70518-3424-01 packaging : 30 1 bottle plastic packaging : 60 1 bottle plastic storage store room temperature 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "celecoxib capsules contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) celecoxib , components product [ ( 5.7 , 5.9 ) ] . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids , reported patients [ ( 5.7 , 5.8 ) ] . setting cabg surgery [ ( 5.1 ) ] . patients demonstrated allergic-type sulfonamides [ ( 5.7 ) ] .",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L"
        }
    ],
    "organization": "REMEDYREPACK INC.",
    "name": "CELECOXIB",
    "effectiveTime": "20250523",
    "indications_original": "Celecoxib capsule are indicated",
    "contraindications_original": "• Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. (2.1 ) • OA: 200 mg once daily or 100 mg twice daily. ( 2.2 , 14.1 ) • RA: 100 to 200 mg twice daily. ( 2.3 , 14.2 ) • JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg. ( 2.4 , 14.3 ) • AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit. ( 2.5 , 14.4 ) • AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed. ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.7 , 8.6 , 12.3 ) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers. ( 2.7 , 8.8 , 12.3 ).",
    "warningsAndPrecautions_original": "Celecoxib capsules 100 mg are white to white opaque hard gelatin capsules, imprinted with  \"CEL\" on cap & \"100 mg\" on body in black ink supplied as:\n                  \n                  \n                  NDC: 70518-3424-00\n                  NDC: 70518-3424-01\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 60 in 1 BOTTLE PLASTIC\n                  \n                  \n                  Storage\n  \nStore at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].\n \n                  \n                     \nRepackaged and Distributed By:\n \n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Celecoxib capsules are contraindicated in the following patients:\n                  \n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product\n  \n   [see\n   \n    Warnings and Precautions (5.7,\n   \n    5.9)]\n  \n   . \n \n  \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been reported in such patients\n  \n   [see\n   \n    Warnings and Precautions (5.7,\n   \n    5.8)]\n  \n   . \n \n  \n                     In the setting of CABG surgery\n  \n   [see\n   \n    Warnings and Precautions (5.1)]\n  \n   . \n \n  \n                     In patients who have demonstrated allergic-type reactions to sulfonamides\n  \n   [see\n   \n    Warnings and Precautions (5.7)]\n  \n   ."
}